What is Raymond James’ Forecast for TSE:PRN FY2024 Earnings?

Profound Medical Corp. (TSE:PRN) – Equities researchers at Raymond James boosted their FY2024 EPS estimates for shares of Profound Medical in a research report issued to clients and investors on Wednesday, December 11th. Raymond James analyst M. Freeman now anticipates that the company will earn ($1.79) per share for the year, up from their prior estimate of ($1.82). Raymond James has a “Strong-Buy” rating on the stock. The consensus estimate for Profound Medical’s current full-year earnings is ($1.90) per share. Raymond James also issued estimates for Profound Medical’s Q4 2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($1.24) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at $1.50 EPS and FY2028 earnings at $3.43 EPS.

Profound Medical Stock Down 1.1 %

PRN stock opened at C$10.56 on Monday. The company has a market cap of C$258.51 million, a P/E ratio of -6.36 and a beta of 0.81. The company has a current ratio of 8.61, a quick ratio of 14.98 and a debt-to-equity ratio of 16.95. The company’s 50-day moving average price is C$10.81 and its 200 day moving average price is C$11.61. Profound Medical has a 52 week low of C$9.55 and a 52 week high of C$15.75.

Insider Transactions at Profound Medical

In other Profound Medical news, Senior Officer Thomas Michael Tamberrino acquired 13,333 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was bought at an average cost of C$10.65 per share, for a total transaction of C$141,996.45. Also, Director Arun Menawat Dr. bought 20,000 shares of the stock in a transaction dated Tuesday, December 10th. The stock was bought at an average price of C$10.65 per share, with a total value of C$213,000.00. Corporate insiders own 8.62% of the company’s stock.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.